Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 340

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 340
---
 and as adopted by the UK and in accordance with International Accounting
Standard 34 Interim Financial Reporting (‘IAS 34’). The interim consolidated financial information does not include all the
information and disclosures required in the annual financial information and should be read in conjunction with the audited financial
statements for the year ended December 31, 2023.

The accounting
policies adopted are consistent with those of the previous financial year and corresponding interim reporting periods.

Book values approximate
to fair value at 30 June 2024, 30 June 2023 and 31 December 2023.

The condensed interim
financial information contained in this interim statement does not constitute statutory financial statements as defined by section 434(3)
of the Companies Act 2006. The condensed interim financial information has not been audited. The comparative financial information for
the six months ended June 30, 2023 and the year ended December 31, 2023 in this interim financial information does not constitute statutory
financial statements for that period or year. The statutory financial statements for December 31, 2023 have been delivered to the UK Registrar
of Companies. The auditor’s report on those accounts was unqualified and did not contain a statement under section 498(2) or 498(3)
of the Companies Act 2006. The auditor’s report did draw attention to a material uncertainty related to going concern and the requirement,
as of the date of the report, for additional funding to be raised by the Company by the fourth quarter of 2024.

Biodexa Pharmaceutical’s
annual reports may be downloaded from the Company’s website at https://biodexapharma.com/investors/financial-reports-and-presentations/#financial-reports
or a copy may be obtained from 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ.

Going Concern – material uncertainty

Biodexa has experienced
net losses and significant cash outflows from cash used in operating activities over the past years as it develops its portfolio. For
the six months to June 30, 2024, the Group incurred a consolidated loss from operations of £3.31 million (1H23: loss £3.56
million) and negative cash flows from operating activities of £4.81 million (1H23 £3.88 million). As of June 30, 2024, the
Group had accumulated deficit of £147.88 million.

The Group’s